In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Arcadia Biosciences (NASDAQ: RKDA), with a price target of $20. The company’s shares closed yesterday at $6.88, close to its 52-week low of $3.60.
Selvaraju observed:
“Valuation methodology, risks and uncertainties. Our valuation utilizes a discounted cash flow-based approach that derives a $130M value for RS Wheat, using a 15% discount rate, 30% tax rate and 10% manufacturing spend.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.2% and a 41.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $66.56 and a one-year low of $3.60. Currently, Arcadia Biosciences has an average volume of 492K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcadia Biosciences, Inc. is an agricultural biotechnology company which engages in the development of agricultural products for the improvement of the environment and human health. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers.
